

LET/17/EJ/28195
26 June 2017

To: Members of SCOPAFF phytopharmaceuticals

Euros Jones
Director Regulatory Affairs
(+32) 2 663 15 53
euros.jones@ecpa.eu

SCOPAFF meeting 4 July 2017, criteria for endocrine disrupting properties

Dear SCOPAFF members

Ahead of the upcoming SCOPAFF-Phytopharmaceuticals meeting on 4 July 2017, we would like to **reiterate our significant concerns regarding the Commission's proposal for the criteria for endocrine disrupting properties**. These concerns remain the same as those contained in our last letter to you of 24 May 2017 attached here again for ease of reference.

According to our information – also reflected in conclusions from at least one SCOPAFF – **we understand that there is a qualified majority of Member States who may be in favour of the criteria if the derogation was to be tabled for a vote**. We are not sure why the Commission will not allow Member States to have their say on the derogation at this point, and fail to see how it can be successfully reintroduced in the future. We also understand that a number of MEPs across Parliamentary Committees, including ENVI, have recently written to both Commissioner Andriukaitis and President Juncker expressing their concern on this issue as well.

We strongly urge the Commission to give Member States the opportunity to decide on the criteria and derogation together, by putting both to a vote on 4 July 2017. We would also strongly urge Member States to vote against the proposal for criteria if the Commission does not table the derogation at the same time.

Yours sincerely



Euros Jones
Director Regulatory Affairs